Dr. Jason Hafron, Chief Medical Officer of the Michigan Institute of Urology, provides a detailed real-world explanation of reimbursement considerations for Jelmyto (mitomycin) in treating upper tract urothelial carcinoma: coverage, coding, and payment. ...
Integrating Innovative Therapies into Practice
Dr. Jason Hafron, Chief Medical Officer of the Michigan Institute of Urology, provides a detailed real-world explanation of reimbursement considerations for Jelmyto (mitomycin) in treating upper tract urothelial carcinoma: coverage, coding, and payment.
Advertisement
Detailing the mitomycin gel adverse events, as well as advice for private practice urologists when offering mitomycin gel.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.